Viatris (VTRS) Other financing activities (2020 - 2026)
Viatris' (VTRS) quarterly Other financing activities came in at -$300000.0 in Q1 2026, up 99.73% year-on-year from -$150205.6 in Q1 2025, and up 97.5% quarter-over-quarter from -$12.0 million in Q4 2025.
Viatris (VTRS) Other financing activities (2020 - 2026) Analysis & Trends
Viatris' Other financing activities history runs 7 years deep, the most recent figure standing at -$300000.0 for Q1 2026.
- On a quarterly basis, Other financing activities rose 99.73% year-over-year to -$300000.0 in Q1 2026; TTM through Mar 2026 was -$80.8 million, a 145.04% decrease from a year earlier, with the FY2025 full-year figure at -$190.1 million, down 164.4% from the prior year.
- Other financing activities advanced to -$300000.0 in Q1 2026 per VTRS's latest filing, from -$12.0 million in the prior quarter.
- Across five years, Other financing activities topped out at $290.4 million in Q4 2024 and bottomed at -$277.2 million in Q4 2023.
- The 5-year median for Other financing activities is $3.0 million (2022), against an average of -$3.1 million.
- Across the five-year window, Other financing activities jumped 17925.0% in 2023 and slumped 1867.74% in 2025, its largest moves.
- Year by year, Other financing activities stood at $19.2 million in 2022, then slumped by 1543.75% to -$277.2 million in 2023, then jumped by 204.76% to $290.4 million in 2024, then sank by 104.13% to -$12.0 million in 2025, then soared by 97.5% to -$300000.0 in 2026.
- Per Business Quant, the three latest VTRS Other financing activities figures stand at -$300000.0 (Q1 2026), -$12.0 million (Q4 2025), and -$179.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -300,000.00 |
| Mar 31, 2026 | -300,000.00 |
| Dec 31, 2025 | -12.00 Mn |
| Dec 31, 2025 | -12.00 Mn |
| Sep 30, 2025 | -179.10 Mn |
| Sep 30, 2025 | -179.10 Mn |
| Jun 30, 2025 | 110.60 Mn |
| Jun 30, 2025 | 110.60 Mn |
| Mar 31, 2025 | -109.60 Mn |
| Mar 31, 2025 | -109.60 Mn |
| Dec 31, 2024 | 290.40 Mn |
| Dec 31, 2024 | 290.40 Mn |
| Sep 30, 2024 | -124.00 Mn |
| Sep 30, 2024 | -124.00 Mn |
| Jun 30, 2024 | 122.60 Mn |
| Jun 30, 2024 | 122.60 Mn |
| Mar 31, 2024 | 6.20 Mn |
| Mar 31, 2024 | 6.20 Mn |
| Dec 31, 2023 | -277.20 Mn |
| Dec 31, 2023 | -277.20 Mn |